Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SGMO | US
0.02
2.78%
Healthcare
Biotechnology
30/06/2024
30/08/2024
0.85
0.82
0.86
0.81
Sangamo Therapeutics Inc. a clinical-stage genomic medicine company focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920 a gene therapy product candidate which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200 a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525 a gene therapy product candidate which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003 a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics Inc. has collaborative and strategic partnerships with Biogen MA Inc.; Kite Pharma Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech Inc.; Open Monoclonal Technology Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences Inc. and changed its name to Sangamo Therapeutics Inc. in January 2017. Sangamo Therapeutics Inc. was incorporated in 1995 and is headquartered in Brisbane California.
View LessHigh 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
63.3%1 month
168.9%3 months
170.6%6 months
141.7%-
-
7.38
1.23
0.31
-1.00
14.35
-
-184.99M
176.57M
176.57M
-
-9.41K
-
-94.80
-194.05
0.50
7.77
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.19
Range1M
0.62
Range3M
0.95
Rel. volume
0.14
Price X volume
1.58M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Mersana Therapeutics Inc | MRSN | Biotechnology | 1.58 | 193.83M | 3.95% | n/a | 383.37% |
MOLECULAR PARTNERS AG | MOLN | Biotechnology | 5.68 | 188.47M | -12.35% | n/a | 1.96% |
Compugen Ltd | CGEN | Biotechnology | 2.1 | 188.03M | 3.45% | n/a | 5.19% |
Inovio Pharmaceuticals Inc | INO | Biotechnology | 7.22 | 187.46M | -1.37% | n/a | 13.42% |
Centrexion Therapeutics Corporation | CNTX | Biotechnology | 2.46 | 184.50M | 0.41% | n/a | 0.00% |
Greenwich LifeSciences Inc | GLSI | Biotechnology | 14.02 | 184.29M | -1.54% | n/a | 0.00% |
CIBUS GLOBAL LTD. | CBUS | Biotechnology | 6.77 | 177.38M | -4.65% | n/a | 81.33% |
Generation Bio Co | GBIO | Biotechnology | 2.64 | 176.20M | -1.49% | n/a | 81.41% |
Rani Therapeutics Holdings Inc. Class A Common Stock | RANI | Biotechnology | 3.2 | 174.94M | 13.48% | n/a | 1243.32% |
Outlook Therapeutics Inc | OTLK | Biotechnology | 7.35 | 173.87M | 0.68% | n/a | -39.11% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 53.7 | 152.52M | -0.37% | 8.42 | 71.47% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14.72 | 92.17M | -2.06% | 14.72 | 7.10% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.38 | 76.89M | 5.34% | n/a | 268.43% |
Emmis Communications Corporation | EMMS | Broadcasting - Radio | 4.7 | 57.98M | -1.05% | n/a | 54.59% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 3.68 | 39.85M | -1.12% | n/a | 54.96% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 2.34 | 28.51M | 13.04% | n/a | 16.03% |
ILAG | ILAG | Building Products & Equipment | 1.25 | 22.57M | 6.84% | n/a | 5.48% |
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 0.6131 | 18.67M | -4.20% | n/a | 204.46% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2495 | 3.93M | 5.94% | n/a | 0.00% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.391 | 3.72M | -6.28% | n/a | 19.98% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -1.00 | 0.97 | Cheaper |
Ent. to Revenue | 14.35 | 3,681.29 | Cheaper |
PE Ratio | - | 39.83 | - |
Price to Book | 7.38 | 14.54 | Cheaper |
Dividend Yield | - | 2.19 | - |
Std. Deviation (3M) | 170.56 | 76.13 | Riskier |
Debt to Equity | 1.23 | -2.05 | Expensive |
Debt to Assets | 0.31 | 0.25 | Expensive |
Market Cap | 176.57M | 4.04B | Emerging |